Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Vitiligo - Overview
Vitiligo - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Vitiligo - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Vitiligo - Companies Involved in Therapeutics Development
Vitiligo - Drug Profiles
Vitiligo - Dormant Projects
Vitiligo - Discontinued Products
Vitiligo - Product Development Milestones
Featured News & Press Releases
Jul 19, 2022: US FDA grants approval to Incyte’s Opzelura cream for vitiligo treatment
May 10, 2022: Clinuvel progresses vitiligo study
May 09, 2022: CLINUVEL progresses vitiligo treatment program
Mar 26, 2022: Incyte announces 52-week data from the phase 3 TRuE-V program evaluating ruxolitinib cream (Opzelura) in patients with vitiligo
Mar 18, 2022: Incyte announces multiple abstracts from its dermatology portfolio have been accepted for presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting
Mar 14, 2022: Incyte announces U.S. FDA has extended the supplemental New Drug Application review period for ruxolitinib cream (Opzelura) for the treatment of vitiligo
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Dec 20, 2021: SCENESSE as vitiligo monotherapy
Dec 14, 2021: Incyte announces acceptance and Priority Review of sNDA for ruxolitinib cream (Opzelura) as a treatment for patients with vitiligo
Oct 28, 2021: Incyte announces the validation of the European Marketing authorization application for Ruxolitinib Cream in Vitiligo
Oct 02, 2021: Incyte announces full results from phase 3 TRuE-V program evaluating ruxolitinib cream (Opzelura) in patients with vitiligo
Sep 13, 2021: Incyte announces ruxolitinib cream data accepted for presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
Jul 01, 2021: Arcutis provides update on phase 2a clinical trial evaluating ARQ-252 cream as a potential treatment for vitiligo
Jul 01, 2021: Arcutis provides update on phase 2a clinical trial evaluating ARQ-252 cream as a potential treatment for vitiligo
May 18, 2021: Incyte’s ruxolitinib meets endpoints in Phase III trials for vitiligo
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Vitiligo, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Vitiligo, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Vitiligo - Pipeline by 2A Pharma AB, 2022
Vitiligo - Pipeline by AbbVie Inc, 2022
Vitiligo - Pipeline by Ahammune Biosciences Pvt Ltd, 2022
Vitiligo - Pipeline by Alexion Pharmaceuticals Inc, 2022
Vitiligo - Pipeline by Almirall SA, 2022
Vitiligo - Pipeline by Amgen Inc, 2022
Vitiligo - Pipeline by AnaptysBio Inc, 2022
Vitiligo - Pipeline by AnTolRx Inc, 2022
Vitiligo - Pipeline by APIRx Pharmaceuticals USA LLC, 2022
Vitiligo - Pipeline by Arrien Pharmaceuticals LLC, 2022
Vitiligo - Pipeline by Avotres Inc, 2022
Vitiligo - Pipeline by Clinuvel Pharmaceuticals Ltd, 2022
Vitiligo - Pipeline by Elixiron Immunotherapeutics Inc, 2022
Vitiligo - Pipeline by Forte Biosciences Inc, 2022
Vitiligo - Pipeline by HysensBio Corp, 2022
Vitiligo - Pipeline by Incyte Corp, 2022
Vitiligo - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Vitiligo - Pipeline by JN Biosciences LLC, 2022
Vitiligo - Pipeline by Pfizer Inc, 2022
Vitiligo - Pipeline by Radikal Therapeutics Inc, 2022
Vitiligo - Pipeline by Rhizen Pharmaceuticals SA, 2022
Vitiligo - Pipeline by Shanghai Icure Biotechnology Co Ltd, 2022
Vitiligo - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
Vitiligo - Pipeline by TagCyx Biotechnologies, 2022
Vitiligo - Pipeline by Technoderma Medicines Inc, 2022
Vitiligo - Pipeline by Temprian Therapeutics Inc, 2022
Vitiligo - Pipeline by TWi Biotechnology Inc, 2022
Vitiligo - Pipeline by Villaris Therapeutics Inc, 2022
Vitiligo - Pipeline by VYNE Therapeutics Inc, 2022
Vitiligo - Dormant Projects, 2022
Vitiligo - Discontinued Products, 2022